fashion -WSS

fashion

author：explore 2025-10-02 19:15:35 - browse：99398

A Exterior of the new Ultragenyx biomanufacturing plant. -- biotech coverage from STAT — Jonathan Wiggs /Globe Staff

Ultragenyx said Thursday afternoon that its gene therapy for a rare liver ailment, glycogen disease type 1A, succeeded in a Phase 3 trial, setting up a potential approval.

Patients with GSD1a, as the condition is often known, have a genetic mutation that prevents them from adequately maintaining blood sugar levels. Once considered fatal, GSD1a can now be controlled with regular doses of cornstarch. But if patients miss a dose, there can be significant, even life-threatening, complications.

In the 49-person, randomized study, patients who received the Ultragenyx drug were able to take 41% less cornstarch after 48 weeks than they did at the start. Patients on placebo took only 10% less. The difference was statistically significant. Five patients were not included in the analysis, as three dropped out and the company didn’t have 48-week data from two.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Guidelines to prevent youth baseball injuries need more muscle
Next article： Questions and answers about ramping up H5N1 bird flu vaccine

WSS

A new drug could help frostbite victims avoid its ravages

Biogen joins immunology wave with $1.15 billion acquisition of HI

New CMS data security rules will hurt Medicare, Medicaid research

Readout Newsletter: Sarepta, Alnylam, and Royalty Pharma

Reports of telehealth's death have been greatly exaggerated

Readout Newsletter: Bayer, Rapt Therapeutics, Sanofi shortage

entertainment

fashion

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

hotspot

Guidelines to prevent youth baseball injuries need more muscle

Questions and answers about ramping up H5N1 bird flu vaccine

Dobbs anniversary: the lost opportunity of abortion as health care

Readout Newsletter: Sarepta, Alnylam, and Royalty Pharma

ChatGPT in medicine: STAT answers readers' burning questions

Making the case for fair compensation in clinical trials

In age of alternative facts, a scholarly course on calling out crap

H5N1 virus can be tracked in retail milk, scientists say

How one medical school became remarkably diverse

Making the case for fair compensation in clinical trials

Wikipedia

In 'major milestone,' FDA approves first cell therapy for solid tumors

Questions and answers about ramping up H5N1 bird flu vaccine

Opioid cravings were reduced by anti

FDA poised to publish guidelines for clinical trial diversity

Bird flu surveillance in wastewater gets boost from consortium

WATCH: Why do our ears pop?

knowledge

hotspot

focus

hotspot